Move to decontrol prices of cardiac, diabetes drugs challenged in SC
11 Oct 2014 4:43 AM IST
Centre’s decision to decontrol prices of 108 cardiac and diabetes drugs was on Thursday challenged before the Supreme Court which agreed to hear the case ‘as soon as possible’.
The PIL alleged that hike in prices of life saving drugs is against the public interest and would lead to windfall gain to the pharmaceuticals companies at the cost of endangering lives of million of Indians.
Advocate ML Sharma, who filed the petition and mentioned the case for urgent hearing, submitted that allowing pharmaceuticals companies to raise price as per their choice to secure wind fall gain involves serious corruption and a life threat to public.
‘There are around 4.1 crore diabetes, 5.7 crore coronary heart disease, 22 lakh TB, 11 lakh cancer, 25 lakh HIV/AIDS and 6 crores blood pressure patients in India which are facing life threat and another life threat due to impugned circular for decontrolling order and price rise in medicines,’ the petition said.
The PIL alleged that hike in prices of life saving drugs is against the public interest and would lead to windfall gain to the pharmaceuticals companies at the cost of endangering lives of million of Indians.
Advocate ML Sharma, who filed the petition and mentioned the case for urgent hearing, submitted that allowing pharmaceuticals companies to raise price as per their choice to secure wind fall gain involves serious corruption and a life threat to public.
‘There are around 4.1 crore diabetes, 5.7 crore coronary heart disease, 22 lakh TB, 11 lakh cancer, 25 lakh HIV/AIDS and 6 crores blood pressure patients in India which are facing life threat and another life threat due to impugned circular for decontrolling order and price rise in medicines,’ the petition said.
Next Story
